Trial Profile

Early access program for doxorubicin liposomal [ThermoDox] in patients with recurrent chest wall breast cancer

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary)
Indications Advanced breast cancer; Liver cancer
Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
10 Aug 2015 Status changed from not yet recruiting to recruiting according to a Celsion Corporation media release.
10 Aug 2015 According to a Celsion Corporation media release, this EAP study was expanded to include patients with primary liver cancer and liver cancer metastases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com